|
Quality of Life in Survivors of Gynecologic Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Quality of Life in Survivors of Gynecologic Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Quality of Life in Survivors of Gynecologic Cancer Clinical research trials and Quality of Life in Survivors of Gynecologic Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Quality of Life in Survivors of Gynecologic Cancer. Quality of Life in Survivors of Gynecologic Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Quality of Life in Survivors of Gynecologic Cancer clinical trial. Participants frequently get the best healthcare available for their Quality of Life in Survivors of Gynecologic Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "Q" Clinical Trials Conditions > Quality of Life in Survivors of Gynecologic Cancer  Quality of Life in Survivors of Gynecologic Cancer
Quality of Life in Survivors of Gynecologic Cancer
For Condition: stage 1 ovarian epithelial cancer,Quality of Life,stage 2 endometrial cancer,stage 2 ovarian epithelial cancer,stage 1 endometrial cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Gynecologic Oncology Group
Synopsis: RATIONALE: Quality-of-life assessment in cancer survivors may help determine the long-term effects of having had gynecologic cancer and may help improve the quality of life for future cancer survivors. PURPOSE: Clinical trial to study quality of life in survivors of gynecologic cancer.
Details: OBJECTIVES: I. Describe the significant quality of life (QOL) concerns and long term survivorship issues of women diagnosed and treated for early stage ovarian and endometrial cancer five or more years ago. II. Identify mechanisms which contribute to a gynecologic cancer survivorship model through comparison and prediction of high versus low QOL associated with long term adjustment and survivorship. Examine social support, coping efforts, self-efficacy, meaning associated with survivorship, performance status, and age at diagnosis as potential predictors. III. Identify and compare factors that predict high versus low QOL for women with early stage endometrial cancer completing participation in GOG-99 clinical trial. Conduct exploratory analysis examining long term QOL concerns of survivors randomized to surgery arm with or without radiotherapy. PROTOCOL OUTLINE: Patients complete one telephone interview with a professional female interviewer. The interview lasts approximately 60 minutes and is audiotaped. PROJECTED ACCRUAL: A total of 197 early stage endometrial cancer survivors and 114 early stage ovarian cancer survivors will be accrued for this study within 2 years.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed early stage ovarian and endometrial cancer survivors treated and diagnosed five or more years ago - Patients completing treatment in GOG-95 or GOG-99 protocols at least 5 years ago with no recurrence of disease - Patients with secondary malignancy or under treatment for other medical conditions are eligible --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: Not specified - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: Must be capable of completing telephone interview in English
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LariWenzel, Study Chair, Gynecologic Oncology Group
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190
United States
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Cooper Hospital/University Medical Center
Camden, New Jersey, 08103
United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
United States
Tacoma General Hospital
Tacoma, Washington, 98405
United States
Cancer Center of Albany Medical Center
Albany, New York, 12208
United States
Comprehensive Cancer Center at Wake Forest University
Winston Salem, North Carolina, 27157-1082
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
United States
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
United States
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
United States
University of Colorado Cancer Center
Denver, Colorado, 80010
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
University of Rochester Cancer Center
Rochester, New York, 14642
United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
United States
Community Hospital of Los Gatos
Los Gatos, California, 95032
United States
New England Medical Center Hospital
Boston, Massachusetts, 02111
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Canada
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, 01655
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
State University of New York Health Sciences Center - Stony Brook
Stony Brook, New York, 11790-7775
United States
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
United States
Holden Comprehensive Cancer Center at The University of Iowa
Iowa City, Iowa, 52242-1009
United States
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, 60612
United States
Brookview Research, Inc.
Nashville, Tennessee, 37203
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Schneider Children's Hospital at North Shore
Manhasset, New York, 11030
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Washington University School of Medicine
St. Louis, Missouri, 63110
United States
Additional Information:
Study ID Numbers: CDR0000066938; GOG-9902
Study Start Date: April 1999
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003795
Other Stage 2 Endometrial Cancer Studies:
1. Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
2. Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer
3. Quality of Life in Survivors of Gynecologic Cancer
4. Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer
5. Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
Related Studies:
Other stage 2 endometrial cancer Clinical Trials
Other New York Clinical Trials
Other Brooklyn Clinical Trials
Quality of Life in Survivors of Gynecologic Cancer
|
|
|
|
|
|
|
|
